Novartis Pharmaceutical Sales Force

Safety Insights for Novartis Pharmaceutical Sales Force

Novartis Pharmaceutical Sales Force operates an establishment with approximately 3,396 full-time equivalent workers in EAST HANOVER, NJ, classified under the Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing industry (NAICS 325412). Across 7 years of mandatory OSHA Injury Tracking Application (ITA) reporting, this employer has accumulated 163 recordable injuries, 19 occupational illnesses, and 1 workplace fatality. The average Total Case Rate (TCR) of 4.5 injuries per 100 full-time workers per year provides the anchor metric for the D letter grade (Poor Safety Record).

Benchmarked against the Bureau of Labor Statistics industry average of 3.3 for Pharmaceutical preparations (e.g., capsules, liniments, ointments, tablets) manufacturing, Novartis Pharmaceutical Sales Force's workforce experiences 138% of the typical injury burden. This ratio matters because TCR already normalizes for hours worked — a 200,000-hour exposure base equals roughly 100 full-time workers — so establishments with very different headcounts can be compared directly. A TCR above the benchmark flags a higher-than-typical risk profile for jobseekers, insurers, and enforcement agencies to examine.

Multi-year trend analysis is the single most reliable signal here: a one-year spike could reflect a single severe event, whereas sustained elevation across 7 reporting cycles points to systemic hazard exposure. Readers evaluating Novartis Pharmaceutical Sales Force as an employer, contractor, investment, or regulatory target should examine the yearly DART rate (days away, restricted, or transferred), the fatality count of 1, and any year-over-year deterioration shown in the table below. All figures come directly from employer-submitted OSHA Form 300A summaries — there is no modeling, estimation, or third-party adjustment layered on top of the government data.